- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess were observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection - DURHAM, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implan ...

To Nasdaq Copenhagen A/S Executive ManagementBernstorffsgade 40DK-1577 København Vwww.rd.dkTelephone +45 7012 530015 September 2025 Company Announcement number 74/2025 Auctions of mortgage covered bonds series 10F and 10G for the refinancing of FlexLån® Realkredit Danmark will hold auctions on mortgage covered bonds (SDRO) for the refinancing of FlexLån® as of 1 January 2026. The auctions in series 10F and 10G will be held in the period from 17 November to 21 November 2025. The preliminary amounts and the ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Adamas Trust, Inc. (Nasdaq: ADAM) (the “Company” or “Adamas”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.23 per share on shares of its common stock for the quarter ending September 30, 2025. The dividend will be payable on October 30, 2025 to common stockholders of record as of the close of business on September 25, 2025. In addition, the Board declared cash dividends on the Company’s 8.000% Series D ...

81% of shippers and logistics services providers view transportation as a competitive weapon; growth and AI adoption driving investments despite automation gap LONDON and ATLANTA, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced the results of its 9th Annual Global Transportation Management Benchmark Survey of more than 600 companies. The study reveals that 81% of the shippers and logistics ...

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / 150,000,000 Units at a price per Unit of C$0.12 for gross proceeds of C$18,000,000225,000,000 Units at a price per Unit of US$0.08711 for gross proceeds of US$19,599,750 KELLOGG, Idaho and VANCOUVER, British Columbia, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR |OTCQB: BHLL) announces today that it has revised the terms of its previously announce ...

150,000,000 Units at a price per Unit of C$0.12 for gross proceeds of C$18,000,000225,000,000 Units at a price per Unit of US$0.08711 for gross proceeds of US$19,599,750 KELLOGG, Idaho and VANCOUVER, British Columbia, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR |OTCQB: BHLL) announces today that it has revised the terms of its previously announced “bought deal” private placement financing to provide for Canadian Dollar and United States Dollar de ...

DallasNews Shareholders to Receive All-Cash Consideration of $16.50 Per Share, a 276% Premium Over the Closing Price Per Share of Series A Common Stock on July 9, 2025 Hearst Merger Provides Certainty of Value, Accelerated ROI, and Immediate Liquidity, While Eliminating Company Ownership Risks for Shareholders Board Unanimously Recommends that Shareholders Vote “FOR” the Hearst Merger to Secure the Future of DallasNews and Realize a Significant Premium on their Investment DALLAS, Sept. 15, 2025 (GLOBE NEWSW ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI; the "Company" or “FTAI”) plans to announce its financial results for the third quarter 2025 after the closing of Nasdaq on Monday, October 27, 2025. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, https://www.ftaiaviation.com/. In addition, management will host a conference call on Tuesday, October 28, 2025 at 8:00 A.M. Eastern Time. The conference ...

Company Announcement No 42/2025Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk15 September 2025 Dear Sirs Sydbank A/S share buyback programme: transactions in week 37On 26 February 2025 Sydbank A/S announced a share buyback programme of DKK 1,350m. The share buyback programme commenced on 3 March 2025 and will be completed by 31 January 2026. The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S and t ...

交易概览 - Ocugen与韩国Kwangdong制药就OCU400达成独家授权协议 授权范围涵盖韩国地区[1] - OCU400是用于治疗视网膜色素变性(RP)的修饰基因疗法 目前处于临床三期阶段[1][5] 财务条款 - Ocugen将获得最高750万美元的首付款及近期开发里程碑付款[2] - 在韩国市场每实现1500万美元销售额 Ocugen可获得150万美元销售里程碑付款 预计商业化前10年销售额达1.8亿美元或更高[2] - Ocugen将获得Kwangdong销售OCU400净销售额25%的特许权使用费[2] - Ocugen将负责OCU400的商业化生产供应[2] 市场机会 - 韩国约有7000名RP患者 相当于美国市场规模的7%[3] - OCU400有望成为一次性终身疗法 为韩国患者提供新治疗选择[4] - 通过此协议 Kwangdong有望成为韩国眼科基因治疗领域的领导者[3] 合作方背景 - Kwangdong是韩国前五大制药和健康企业 拥有处方药和OTC健康产品组合[4] - Kwangdong正在开发老花眼和儿童近视管线 此次合作将加强其眼科产品组合[5] - Kwangdong在韩国制药和健康公司中排名前十[9] 开发进展 - OCU400目前处于临床三期阶段 目标于2026年向美国FDA提交生物制剂许可申请(BLA)[5] - Kwangdong计划利用Ocugen的临床数据和BLA申请作为韩国监管提交的一部分[6] - 完成临床试验后 Kwangdong将尽快推动产品在韩国上市[5]